Conexiant
Login
  • The Analytical Scientist
  • The Cannabis Scientist
  • The Medicine Maker
  • The Ophthalmologist
  • The Pathologist
  • The Traditional Scientist
The Medicine Maker
  • Explore

    Explore

    • Latest
    • Features
    • Interviews
    • Business & Trends
    • Technology & Manufacturing
    • Product Profiles
    • White Papers

    Featured Topics

    • Biopharma
    • Small Molecules
    • Cell & Gene
    • Future of Pharma

    Issues

    • Latest Issue
    • Archive
    • Cell and Gene Therapy Supplement
  • Topics

    Topics

    • Drug Discovery
    • Development & Clinical
    • Formulation
    • Drug Delivery
    • Bioprocessing
    • Small Molecules
    • Cell and Gene
    • Facilities & Equipment
    • Outsourcing
    • Packaging
    • Supply Chain
    • Regulation & Standards
  • News & Blogs

    News & Blogs

    • Industry News
    • Research News
    • Blogs
  • Events
    • Live Events
    • Webinars
  • Community & Awards

    Community & Awards

    • Power List
    • Sitting Down With
    • Innovation Awards
    • Company of the Year Awards
    • Authors & Contributors
  • Multimedia
    • Video
    • Podcasts
    • eBooks
Subscribe
Subscribe
The Medicine Maker / Issues / 2020 / Articles / Nov / Advanced Medicine in Brief
Manufacture Advanced Medicine

Advanced Medicine in Brief

A $4-billion acquisition, a key finding for sarcopenia drug development, and algorithmic efficiency… What’s new in advanced medicine?

By James Strachan 11/25/2020 1 min read Quick Read (pre 2022)

Share

  • Bayer is paying $2 billion upfront and up to $2 billion in success-based milestone payments to acquire gene therapy developer AskBio. AskBio has a pipeline of gene therapies, including programs for Parkinson's, congestive heart failure, and Pompe disease in early human trials. “Instead of going to Wall Street and every quarter trying to make milestones, we have one financial partner with which we're trying to bring this technology to fruition,” said Sheila Mikhail, AskBio CEO (1).
  • Losing muscle mass is a significant problem for older people and is partly due to a loss of the regenerative functions of satellite cells. Now, a team of researchers mainly based in Spain have found a subgroup of satellite cells that, due to FoxO activation, maintain their regenerative capacity over time, declining only at geriatric age. The scientists hope that their findings will help “harness the potential of stem cells for regenerative medicine in sarcopenia (2).”
  • Techniques to culture and control cells have improved a lot over the years, but finding the perfect conditions to keep undifferentiated cells alive and prevent them from acquiring a different cellular state remains tricky. Now, researchers in Singapore and Australia have developed a computational biology algorithm called EpiMogrify, which predicts factors that maintain cell state in vitro and identifies factors that induce cell conversion. The team reported a significant increase in the efficiency of astrocyte and cardiomyocyte differentiation using EpiMogrify-predicted factors for conversion conditions. (3)


Want to stay up to date with all the advanced medicine news each week? Subscribe – for free – to The Cell + Gene Curator:  https://www.texerenewsletters.com/covid19newsletter

Newsletters

Receive the latest analytical science news, personalities, education, and career development – weekly to your inbox.

Newsletter Signup Image

References

  1. Bayer, “Bayer Acquires Asklepios BioPharmaceutical to Broaden Innovation Base in Cell and Gene Therapy” (2020). Available at: https://bit.ly/3e9dbKG 
  2. L Garcia-Prat et al., “FoxO maintains a genuine muscle stem-cell quiescent state until geriatric age” Nat Cell Bio (2020). 
  3. US Kamaraj et al., “EpiMogrify Models H3K4me3 Data to Identify Signaling Molecules that Improve Cell Fate Control and Maintenance” Cell Syst (2020).

About the Author(s)

James Strachan

Over the course of my Biomedical Sciences degree it dawned on me that my goal of becoming a scientist didn’t quite mesh with my lack of affinity for lab work. Thinking on my decision to pursue biology rather than English at age 15 – despite an aptitude for the latter – I realized that science writing was a way to combine what I loved with what I was good at. From there I set out to gather as much freelancing experience as I could, spending 2 years developing scientific content for International Innovation, before completing an MSc in Science Communication. After gaining invaluable experience in supporting the communications efforts of CERN and IN-PART, I joined Texere – where I am focused on producing consistently engaging, cutting-edge and innovative content for our specialist audiences around the world.

More Articles by James Strachan

False

Advertisement

Recommended

False

Related Content

Don’t Forget CDx Developers
Advanced Medicine
Don’t Forget CDx Developers

November 7, 2014

0 min read

Many drug developers are going ‘full steam ahead’ with personalized medicine strategies. They would be wise to consider a more equitable business model for an essential partner in the process: the developer of the companion diagnostic.

The Next Decade of Cell and Gene Therapies
Advanced Medicine Bioprocessing - Upstream & Downstream Trends & Forecasts Digital Technologies
The Next Decade of Cell and Gene Therapies

May 7, 2025

5 min read

Off-the-shelf allogeneic CAR-Ts, increased manufacturing productivity led by digital systems, and more; we ask experts about the future of advanced medicine.

Peter Marks Resigns from FDA
Standards & Regulation Profession Vaccines Advanced Medicine
Peter Marks Resigns from FDA

April 1, 2025

3 min read

Resignation letter states: “truth and transparency” around vaccines are not desired by Health Secretary RJK Jr. “Rather he wishes subservient confirmation of his misinformation and lies.”

The Trump Effect on Cell and Gene: Science versus Shockwaves
Business Practice Standards & Regulation Trends & Forecasts Advanced Medicine
The Trump Effect on Cell and Gene: Science versus Shockwaves

April 1, 2025

9 min read

Audrey Greenberg on FDA staffing cuts, Peter Marks’ resignation, CDMO pressure, IP migration, AI acceleration, and what CGT needs now to stay on track.

The Medicine Maker
Subscribe

About

  • About Us
  • Work at Conexiant Europe
  • Terms and Conditions
  • Privacy Policy
  • Advertise With Us
  • Contact Us

Copyright © 2025 Texere Publishing Limited (trading as Conexiant), with registered number 08113419 whose registered office is at Booths No. 1, Booths Park, Chelford Road, Knutsford, England, WA16 8GS.